Kazia Therapeutics Proposes Tranched Public Offering

05:41 PM EDT, 08/27/2026 (MT Newswires) -- Kazia Therapeutics (KZIA) said late Thursday it has commenced a tranched registered public offering of American depositary shares, each representing 500 ordinary shares, or pre-funded warrants to purchase ADSs in lieu of ADSs for certain investors, along with accompanying Series A warrants, which are exercisable immediately at an exercise price equal to 115% of the initial public offering price per ADS and accompanying warrants. The offering expires upon the earlier of 30 days after Kazia Therapeutics' stage IV triple-negative breast cancer data readout, expected in the second half of 2027, or the five-year anniversary of issuance, the company said. The accompanying Series B warrants are exercisable immediately at an exercise price equal to 125% of the initial public offering price per ADS and accompanying warrants, and expire upon the earlier of 30 days following the HR+/HER2- data readout, expected in the first half of 2028, or the five-year anniversary of issuance, the company added. Kazia said it plans to use the net proceeds to fund clinical development of paxalisib, including ongoing and planned studies in triple-negative breast cancer and HR+/HER2- breast cancer and other oncology indications, and for working capital and general corporate purposes.